Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation. It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. The first agent approved for the treatment of PAH was epoprostenol, a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature. The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options.
Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.
The FDA has indicated treprostinil for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability. It is also used to treat pulmonary arterial hypertension in patients requiring transition from epoprostenol. The Health Canada label specifies that treprostinil is indicated for the long-term treatment of pulmonary arterial hypertension in NYHA Class III and IV patients who did not respond adequately to conventional therapy.
L24244
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Lucile Packard Children's Hospital, Stanford, Palo Alto, California, United States
UCLA Medical Center, Los Angeles, California, United States
Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, United States
Abhinav Humar, Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Harbor-UCLA Medical Center, Torrance, California, United States
University of CA, San Francisco, San Francisco, California, United States
University of Arizona, Tucson, Arizona, United States
Unité de Pharmacologie Clinique, Inserm CIC3, CHU Grenoble, Grenoble, France
University of California, Los Angeles, Los Angeles, California, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Emory Univeristy, Atlanta, Georgia, United States
David Geffen School of Medicine, UCLA, Los Angeles, California, United States
THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center, New York, New York, United States
University of California San Francisco (UCSF) Medical Center, San Francisco, California, United States
Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.